Last Updated: August 11, 2026

Details for Patent: 11,851,407

Name: Drug Patent Intelligence for US Patent 11851407
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,851,407 protect, and when does it expire?

Patent 11,851,407 protects PYLARIFY and PYLARIFY TRUVU and is included in two NDAs.

This patent has twenty-seven patent family members in seventeen countries.

Summary for Patent: 11,851,407

Title:	Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL
Abstract:	Methods, and related compositions, for the improved synthesis of [18F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [18F]DCFPyL so produced.
Inventor(s):	Hayden T. Ravert, Daniel P. Holt, Ying Chen, Ronnie C. Mease, Hong Fan, Martin G. Pomper, Robert F. Dannals
Assignee:	Johns Hopkins University
Application Number:	US17/195,895
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Device;
Patent landscape, scope, and claims:	error: insufficient information More… ↓ ⤷ Start Trial

Drugs Protected by US Patent 11,851,407

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Progenics Pharms Inc	PYLARIFY	piflufolastat f-18	SOLUTION;INTRAVENOUS	214793-001	May 26, 2021		RX	Yes	Yes	11,851,407	⤷ Start Trial	Y	Y		METHOD OF POSITRON EMISSION TOMOGRAPHY (PET) IN MEN WITH PROSTATE CANCER	⤷ Start Trial
Aphelion	PYLARIFY TRUVU	piflufolastat f-18	SOLUTION;INTRAVENOUS	220089-001	Mar 6, 2026		RX	Yes	Yes	11,851,407	⤷ Start Trial	Y	Y		POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,851,407

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3026889	⤷ Start Trial
Canada	3240630	⤷ Start Trial
China	109563038	⤷ Start Trial
Denmark	3481804	⤷ Start Trial
European Patent Office	3481804	⤷ Start Trial
European Patent Office	4497477	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.